Cumulus has been established to identify, evaluate and, where appropriate, in-license oncology assets with strong value creation opportunities. These will then be developed with a deep understanding of the biological relevance and clinical context. This includes combination settings as well as a focus on molecularly defined patient groups where strong data exits support the clinical utility of these combinations in the specific patient sub-groups.
A focused and rigorous two-year period of evaluation and negotiation has resulted in a short-list of assets at the preclinical and clinical stages of development. The first asset in the DNA repair area was in-licensed in May 2019 >